Clinical trial • Phase I • Cardiology
MK-1824 for Heart failure with preserved ejection fraction
Phase I trial of MK-1824 for Heart failure with preserved ejection fraction. 16 participants.
Overview
- Trial Therapeutic Area
- Cardiology
- Trial Disease
- Heart failure with preserved ejection fraction
- Trial Stage
- Phase I
Key dates
- Initial CTIS Submission Date
- 08-04-2026
- First CTIS Authorization Date
- 12-05-2026
Trial design
Phase I trial in Belgium.
- Target Sample Size
- 16
Recruitment
- Planned Sample Size
- 16
- Recruitment Window Months
- 2
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 16
Belgium
- Earliest CTIS Part Ii Submission Date
- 30-04-2026
- Latest Decision Or Authorization Date
- 12-05-2026
- Processing Time Days
- 12
- Number Of Sites
- 1
- Number Of Participants
- 16
Sites
- Site Name
- UZ Leuven
- Department Name
- Center for Clinical Pharmacology
- Contact Person Name
- Jan de Hoon
- Contact Person Email
- jan.dehoon@uzleuven.be
Sponsor
Primary sponsor
- Full Name
- Merck Sharp & Dohme LLC
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- United States
Investigational products
- Investigational Product Name
- MK-1824
Related trials
Other published trials that may interest you.
- Dapagliflozin for Heart failure with preserved ejection fraction
- CINNARIZINE for Heart failure with preserved ejection fraction
- MELDONIUM for Heart failure with preserved ejection fraction
- METHYLPREDNISOLONE for Fulminant myocarditis
- PELACARSEN for Cardiovascular disease | Arteriosclerotic cardiovascular disease